Alan Greener, PhD, has joined Primordial Genetics Inc. as Vice President of R&D. Alan has extensive experience developing advanced microbial strains for protein production. His addition to the Primordial Genetics team represents a strategic shift in the company’s focus towards discovery and production of high-value proteins, including therapeutic proteins and industrial enzymes.
Alan received his Bachelors degrees in Biology and Mathematics from Brooklyn College and his Ph.D. in Genetics from the Pennsylvania State University Medical School in Hershey, PA. After a Postdoctoral Fellowship at the University of California, San Diego studying plasmid DNA replication, he entered the commercial biotechnology field. In the past 25 years, Alan has held high-level R&D positions at Stratagene and at Gene Therapy Systems. In both companies, he developed numerous E. coli strains with higher transformation efficiency, improved yield of recombinant protein and improved recombinant protein solubility. He also developed hosts for random and site-directed mutagenesis, a topoisomerase-mediated cloning host, and strains to reduce rearrangements within cloned DNA segments. All of these strains were developed and released as commercial products. In addition, he holds patents for inventing methods for error-free PCR cloning and infecting mammalian cells with a bacterial virus. Alan will be drawing on this expertise to develop superior bacterial host strains for protein production using the Function Generator™ platform technology.
Alan Greener joins Primordial Genetics as Vice President, Research and Development
(858) 366-0770 info@primordialgenetics.com
-
Primordial Genetics closes new financing round and adds private equity investors
Sabrina Baffert, , News, 0
Primordial Genetics today announced the first closing of its Series A-2 financing round, including a group of 5 private...
-
Primordial Genetics Awarded $1.15M Grant from the National Institute of General Medical Sciences for Revolutionary Ways to Manufacture Therapeutics and Vaccines
Primordial Genetics, , News, biotechnology, mRNA, National Institute of General Medical Sciences, NIH, Primordial Genetics, RNA, Synthetic Biology, 0
The National Institute of General Medical Sciences at the National Institutes of Health has awarded a Pharmacology, Physiology, and...
-
-
Richard Schneeberger PhD, MBA joins Primordial Genetics as business consultant
Sabrina Baffert, , News, 0
Richard Schneeberger, PhD, MBA has joined Primordial Genetics Inc as acting Director of Business Development. Richard Schneeberger, PhD, MBA...
-
Primordial Genetics and Denovium Collaborate to Impact the Diagnosis, Prevention & Treatment of Human Diseases
Primordial Genetics, , News, artificial intelligence, Denovium Inc., DNA synthesis, Helge Zieler, National Human Genome Research Institute of the National Institutes of Health, Primordia Genetics, Synthetic Biology, Toby Richardson, 0
The Research is Supported by the National Human Genome Research Institute of the National Institutes of Health Primordial Genetics,...
-
Primordial Genetics Inc. awarded a National Science Foundation Phase I STTR grant
Sabrina Baffert, , News, 0
Primordial Genetics Inc has been awarded a Phase I STTR grant in collaboration with Animesh Ray’s laboratory at the Keck...
-
-
Primordial Genetics signs R&D Agreement for pharmaceutical manufacturing.
Sabrina Baffert, , News, 0
Following the launch of an R&D project for improvement of an enzyme used for manufacturing high-value pharmaceuticals in November...